skip to Main Content

Welcome

Celebrating Over 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

ADVOCACY UPDATES

Congress Considers Extension of Telehealth Flexibilities Post-Pandemic

The COVID-19 pandemic forced Congress and the Centers for Medicare & Medicaid Services (CMS) to…

Read more

Changes To E/M Codes Beginning On January 1st

Effective January 1, 2021, the Centers for Medicare & Medicaid (CMS) finalized significant changes to…

Read more

Additional COVID-19 Relief Up in the Air

House Speaker Nancy Pelosi (D-CA) and Treasury Secretary Steven Mnuchin appeared to be moving closer…

Read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

04/01/23: Fellow Exam Application Deadline
Learn more

06/01/23: Research Grant Cycle
Learn more

06/26/23: Membership Application Deadline to be eligible for AAOA Member rate for the 2023 Basic Course

07/01/23: Scientific Abstract Submission Deadline
Learn more

12/01/23: Research Grant Cycle
Learn more

EDUCATION

2023 AAOA Basic Course

The hybrid 2023 AAOA Basic Course in Allergy & Immunology will take place from Thursday, June 29 – Saturday, July 1, 2023 at the Hyatt Regency, Seattle, WA & Virtually. The Pre-Work On-Demand content will be released on Thursday, June 1, 2023. The Post Course On-Demand Access will be available until September 1, 2023. Learn More and Register Today

RESIDENTS

For information about Resident opportunities, DosedDaily, research grants, and other resources. Learn More

IFAR

Available Now

aaoaf-ifar

IFAR Impact Factor: 2.454

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

AAOA Educational Stacks
Next Availability - November 1, 2023

2023 AAOA Advanced Course in Allergy & Immunology - Hybrid
March 30 - April 1, 2023
The Hythe Vail
Formerly the Vail Marriott Mountain Resort
Learn More and Register

2023 AAOA Basic Course in Allergy & Immunology - Hybrid
June 1 - Pre-Work On-Demand
June 29 – July 1 - Live
September 1 - Access
Hyatt Regency Seattle
Learn More and Register

2023 AAOA Annual Meeting - Hybrid
September 29 – October 1, 2023
Embassy Suites by Hilton Nashville Downtown
Learn More and Register

USP 797 Online Module
Learn More and Register

News and Updates

Sore Throat Becoming Dominant COVID Symptom

You are encouraged to remain vigilant when any symptoms of URI emerge, especially as COVID…

Read more

Helping Private Practices Navigate Non-Essential Care During COVID-19

The American Medical Association has released updated guidance for private practice physicians navigating the provision…

Read more
College Allergy Symptoms Treatment Back to Shcool

PRACTICE RESOURCES

AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More

PARTNER RESOURCE CENTER

AAOA has launched a Partner Resource Center to bring you partner resources that can assist your practice and patient care.

Visit the New Center>

PATIENT CORNER

American Elm Shortage

American Elm is dying from Dutch Elm Disease. This may explain the concentrate shortage many practices and antigen suppliers are experiencing.

To help, there are many other elm species that are more or less resistant to this fungal disease and still cause allergic symptoms.  There is little cross-reactivity outside the elm family, so the best bet to overcome the shortage and help your patients is to substitute another elm species for allergen testing and immunotherapy.

Several Elm species are commercially available, including Slippery Elm and Chinese Elm.  Other options to consider include Mulberry, Hemp, and Hops — all closely related.  None of these substitutes are going to be exact matches, either for antigen profile or for potency.  Additionally, you can discuss further with the pharmacist at your Antigen source company to identify the most readily available cross-reactive option.  

Whichever you choose to use to replace American Elm will require mandatory vial testing for each patient who is switched to the new antigen. Best option to consider when replacing American Elm for Chinese Elm on your mixing board is to cut back one 5-fold dilution (5-fold) and then do a vial check.  Retesting is not necessary.  

For those with patients on monthly maintenance injections, you may need to re-escalate. With the recommendation of  a 1:5 dilution with the addition of the new Elm product, that implies the need for re-escalating back to the maintenance dose. If the patient is on monthly injections, and you use the standard AAOA escalation, it would take nearly 2 years to get back up to full maintenance dose or the patient will need to go back to weekly injections for five months until get back to full maintenance. You may want to consider a more rapid weekly re-escalation for a patient already on monthly maintenance, such as 0.1, 0.2, 0.3, 0.4, and 0.5 , which would cut down on the time to get back to full maintenance. This should be reasonably safe due to the cross-reactivity. 

Back To Top